Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atea Pharmaceuticals Inc
(NQ:
AVIR
)
3.630
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Atea Pharmaceuticals Inc
< Previous
1
2
Next >
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
August 28, 2024
New Data Further Elucidates Bemnifosbuvir’s Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA...
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
July 31, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
June 05, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 29, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
May 22, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
May 07, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
April 29, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
March 27, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
February 21, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
January 08, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 13, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 02, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
November 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
June 15, 2023
Combination Offers Opportunity to Improve Standard of Care with Potential for Short Duration, Protease Inhibitor-Free Treatment
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 05, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 30, 2023
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 23, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Highlighted for Surprising Price Action
May 22, 2023
Via
Investor Brand Network
Exposures
COVID-19
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
May 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.